Missing/wrong data?
Log in to edit
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
scientific article
Author/s
author: Guillaume Cartron, Gilles Salles, Noel Jean Milpied, Catherine Thieblemont, Franck Morschhauser, Elina Asikanius
Work details
Publication date
March 19, 2012
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.